While expected, Intercept's approval delay adds to NASH uncertainty

Submitted by admin on January 18, 2020 - 7:33pm

Source:

BioPharma Dive

News Tags:

Intercept Pharma

NASH

FDA

obeticholic acid

Headline:

While expected, Intercept's approval delay adds to NASH uncertainty

snippet:

In a Friday disclosure, Intercept Pharmaceuticals said it could take up to three months longer for regulators to make an approval decision on the company's closely watched liver disease drug. The approval deadline is now set for June 26 rather than March 26.

Search form

You are here

While expected, Intercept's approval delay adds to NASH uncertainty

While expected, Intercept's approval delay adds to NASH uncertainty